First ever MASH drug primed for big impact in USA
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals...
Research suggests there will likely be strong uptake for the first USA-approved therapy for metabolic dysfunction-associated steatohepatitis (MASH). Madrigal Pharmaceuticals...
Madrigal Pharmaceuticals already has physicians singing from its hymn sheet. Shortly after the biotech won approval in metabolic dysfunction-associated steatohepatitis...
Despite Boehringer Ingelheim’s 2021 Humira biosimilar approval being heralded by some analysts as a “landmark achievement” for the field, the...
With three relatively new drugs, plus a busy pipeline in both systemic lupus erythematosus (SLE) and lupus nephritis (LN), the...
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential...
To gauge the impact and evolving landscape of HS treatment post-secukinumab approval, Spherix Global Insights conducted research with more than...
A chart review completed by Spherix Global Insights shows that more nephrologists are using SGLT2 inhibitors to treat patients with...
News pertaining to biosimilars came at a fast and furious pace in 2023. This was the year of the big...
According to results of a recent survey, more than 80% of U.S.-based neurologists agreed that a major unmet need in...
Bariticinib (Olumiant; Eli Lilly) is prescribed by the majority of US dermatologists to their patients with alopecia areata (AA), according...
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of...
PHILADELPHIA — Results of a survey conducted in the U.S. and abroad showed that most nephrologists remain wary about prescribing...